Your browser doesn't support javascript.
loading
Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations.
Gintant, Gary; Kaushik, Emily Pfeiffer; Feaster, Tromondae; Stoelzle-Feix, Sonja; Kanda, Yasunari; Osada, Tomoharu; Smith, Godfrey; Czysz, Katherine; Kettenhofen, Ralf; Lu, Hua Rong; Cai, Beibei; Shi, Hong; Herron, Todd Joseph; Dang, Qianyu; Burton, Francis; Pang, Li; Traebert, Martin; Abassi, Yama; Pierson, Jennifer Beck; Blinova, Ksenia.
Afiliación
  • Gintant G; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, 60064, USA. Electronic address: gary.gintant@abbvie.com.
  • Kaushik EP; Takeda Pharmaceutical Co, Cambridge, MA, 02139, USA. Electronic address: emily.kaushik@takeda.com.
  • Feaster T; Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, 20993, USA. Electronic address: tromondae.feaster@fda.hhs.gov.
  • Stoelzle-Feix S; Nanion Technologies, Munich, Germany. Electronic address: sonja.stoelzle-feix@nanion.de.
  • Kanda Y; Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan. Electronic address: kanda@nihs.go.jp.
  • Osada T; LSI Medience Corporation, Tokyo, Japan. Electronic address: osada.tomoharu@mg.medience.co.jp.
  • Smith G; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, UK; Clyde Biosciences Ltd., Scotland, UK. Electronic address: godfrey.smith@glasgow.ac.uk.
  • Czysz K; Fujifilm Cellular Dynamics, Inc., Madison, WI, 53711, USA. Electronic address: katherine.czysz@fujifilm.com.
  • Kettenhofen R; Fraunhofer-Institute for Biomed Engineering IBMT, Sulzbach, Germany. Electronic address: ralf.kettenhofen@ibmt.fraunhofer.de.
  • Lu HR; Nonclinical Safety, Johnson & Johnson R&D, Beerse, Belgium. Electronic address: hlu@its.jnj.com.
  • Cai B; Takeda California, Inc., San Diego, CA, 92121, USA. Electronic address: beibei.cai@gmail.com.
  • Shi H; Bristol-Myers Squibb, New York, NY, 10016, USA. Electronic address: hong.shi@bms.com.
  • Herron TJ; Frankel Cardiovascular Regeneration Core Laboratory, University of Michigan, Ann Arbor, MI, 48109, USA. Electronic address: toddherr@umich.edu.
  • Dang Q; Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA. Electronic address: qianyu.dang@fda.hhs.gov.
  • Burton F; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, UK; Clyde Biosciences Ltd., Scotland, UK. Electronic address: francis.burton@glasgow.ac.uk.
  • Pang L; Division of Systems Biology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, 72079, USA. Electronic address: li.pang@fda.hhs.gov.
  • Traebert M; Novartis Inst Biomed Res, Switzerland. Electronic address: martin.traebert@novartis.com.
  • Abassi Y; Agilent Technologies, San Diego, CA, 92121, USA. Electronic address: yama.abassi@agilent.com.
  • Pierson JB; Health and Environmental Sciences Institute, Washington, DC, 20005, USA. Electronic address: jpierson@hesiglobal.org.
  • Blinova K; Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, 20993, USA. Electronic address: ksenia.blinova@fda.hhs.gov.
Regul Toxicol Pharmacol ; 117: 104756, 2020 Nov.
Article en En | MEDLINE | ID: mdl-32822771
ABSTRACT
Human stem cell-derived cardiomyocytes (hSC-CMs) hold great promise as in vitro models to study the electrophysiological effects of novel drug candidates on human ventricular repolarization. Two recent large validation studies have demonstrated the ability of hSC-CMs to detect drug-induced delayed repolarization and "cellrhythmias" (interrupted repolarization or irregular spontaneous beating of myocytes) linked to Torsade-de-Pointes proarrhythmic risk. These (and other) studies have also revealed variability of electrophysiological responses attributable to differences in experimental approaches and experimenter, protocols, technology platforms used, and pharmacologic sensitivity of different human-derived models. Thus, when evaluating drug-induced repolarization effects, there is a need to consider 1) the advantages and disadvantages of different approaches, 2) the need for robust functional characterization of hSC-CM preparations to define "fit for purpose" applications, and 3) adopting standardized best practices to guide future studies with evolving hSC-CM preparations. Examples provided and suggested best practices are instructional in defining consistent, reproducible, and interpretable "fit for purpose" hSC-CM-based applications. Implementation of best practices should enhance the clinical translation of hSC-CM-based cell and tissue preparations in drug safety evaluations and support their growing role in regulatory filings.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Arritmias Cardíacas / Guías de Práctica Clínica como Asunto / Miocitos Cardíacos / Células Madre Adultas / Cardiotoxinas / Estudios de Validación como Asunto Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Regul Toxicol Pharmacol Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Arritmias Cardíacas / Guías de Práctica Clínica como Asunto / Miocitos Cardíacos / Células Madre Adultas / Cardiotoxinas / Estudios de Validación como Asunto Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Regul Toxicol Pharmacol Año: 2020 Tipo del documento: Article